NewLink will review clinical programs after Merck, Incyte trial failure
NewLink Genetics Corp. plans to review its clinical programs after the failure of a similar drug in a Merck and Incyte clinical trial. NewLink noted that the mechanism of its drug, an IDO pathway inhibitor called indoximod, was different from other such products but said that it will nonetheless conduct a clinical program review because of the Incyte news. NewLink shares plummeted nearly 45% in Friday trade after Merck and Incyte said a trial testing their two drugs in combination did not meet its primary endpoint and that they are stopping the trial. NewLink shares have dropped nearly 55% over the last three months to $4.09, compared with a 5.4% drop in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.